Medicare Obesity Drug Coverage May Shift Imaging Demand
As Medicare moves toward covering new obesity medicines, experts anticipate downstream effects on imaging utilization. Imaging leaders should monitor how expanded coverage could alter procedure mix and referral patterns, particularly for modalities tied to cardiovascular, liver, and orthopedic diagnostics.
A new Medicare pilot program for GLP-1 obesity drugs like Ozempic and Wegovy is set to launch in mid-2026. This initiative will make these medications available to qualified Medicare beneficiaries for a $50 monthly copay. To qualify, individuals must be obese or overweight with a related health condition. This expanded coverage is expected to apply to 10 percent of Medicare beneficiaries. The increased use of these effective weight-loss drugs is anticipated to have a ripple effect on medical imaging. Studies have shown that GLP-1 agonists can lead to significant changes in body composition, including reductions in visceral fat, liver volume, and inflammation. These changes could decrease the long-term demand for imaging related to cardiovascular disease, fatty liver disease, and certain orthopedic issues. This shift coincides with a broader trend of imaging services moving from hospitals to outpatient settings. Approximately 40% of all radiology volume is now performed in outpatient centers. This move is driven by lower costs, greater patient convenience, and site-neutral payment policies. Shifting just 10% of hospital-based care to outpatient facilities could save an estimated $125 billion annually. The mobile imaging market is also poised for significant growth, with projections expecting it to reach $21.13 billion by 2031. This growth is fueled by the demand for more accessible and convenient care, especially in rural and underserved areas. Mobile units provide advanced imaging technology without the large upfront capital expense of building a fixed suite. Radiology practices are simultaneously navigating a complex administrative landscape. Prior authorization remains a significant bottleneck, with physicians spending an average of 13 hours per week on these requests. Additionally, complying with regulations like HIPAA can cost practices between $25,000 and $100,000 annually. Artificial intelligence is rapidly being integrated into radiology to address some of these challenges. The FDA has already approved over 1,000 AI-powered tools for clinical imaging, with nearly 80% of all approved medical AI devices being radiology-specific. These AI applications can assist with image interpretation, workflow triage, and automated reporting, helping to improve efficiency and accuracy.
